Lunit to be Listed on KOSDAQ next week
Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000To be listed on the KOSDAQ market on...
Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000To be listed on the KOSDAQ market on...
PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studiesFLORHAM PARK, N.J., July 14, 2022 (GLOBE...
Ideagen’s PleaseReview will improve review, co-authoring and redaction projects linked to cancer and other oncology treatments US-based pharmaceutical company, Immunomedics, is...
Xenikos is currently preparing to initiate a U.S. pivotal Phase 3 trial.Receiving Fast Track designation from the FDA will facilitate...